Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Current Infectious Disease Reports
Erschienen in: Current Infectious Disease Reports 4/2013

01.08.2013 | Cardiovascular Infections (D Levine, Section Editor)

Impact of Antiplatelet Therapy on Clinical Manifestations and Outcomes of Cardiovascular Infections

verfasst von: Ammar Habib, Larry M. Baddour, M. Rizwan Sohail

Erschienen in: Current Infectious Disease Reports | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Despite advances in medical and surgical management, infective endocarditis remains associated with significant morbidity and mortality. Septic embolization to the brain and other organs is one of the most dreaded complications of infective endocarditis. Given the critical role of platelets in bacterial vegetation formation on cardiac valves or cardiac device leads, antiplatelet agents, including aspirin, have recently generated much interest as adjunctive therapies in cardiovascular infections. In this article, we review the published evidence evaluating the role of platelets in the pathogenesis of cardiovascular infections and the rationale for using antiplatelet agents in these infections.
Literatur
1.
Le KY, Sohail MR, Friedman PA, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Hear Rhythm. 2011;8:1678–85.CrossRef
2.
Sohail MR, Henrikson CA, Braid-Forbes MJ, Forbes KF, Lerner DJ. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med. 2011;171:1821–8.PubMedCrossRef
3.
Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol. 2007;49:1851–9.PubMedCrossRef
4.
Tleyjeh IM, Steckelberg JM, Murad HS, et al. Temporal trends in infective endocarditis: a population-based study in Olmsted County, Minnesota. JAMA. 2005;293:3022–8.PubMedCrossRef
5.
Vilacosta I, Graupner C, San Roman JA, et al. Risk of embolization after institution of antibiotic therapy for infective endocarditis. J Am Coll Cardiol. 2002;39:1489–95.PubMedCrossRef
6.
Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52:e1–142.PubMedCrossRef
7.
Kim DH, Kang DH, Lee MZ, et al. Impact of early surgery on embolic events in patients with infective endocarditis. Circulation. 2010;122:S17–22.PubMedCrossRef
8.
Clawson CC, Rao GH, White JG. Platelet interaction with bacteria. IV. Stimulation of the release reaction. Am J Pathol. 1975;81:411–20.PubMed
9.
Fowler VG Jr, Scheld W, Bayer AS. Endocarditis and Intravascular Infections. In: Mandell GLBJ, Dolin R, editors. Principles and Practice of Infectious Diseases. 7th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2009.
10.
Kupferwasser LI, Yeaman MR, Shapiro SM, et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation. 1999;99:2791–7.PubMedCrossRef
11.
Scheld WM, Valone JA, Sande MA. Bacterial adherence in the pathogenesis of endocarditis. Interaction of bacterial dextran, platelets, and fibrin. J Clin Invest. 1978;61:1394–404.PubMedCrossRef
12.
Kupferwasser LI, Yeaman MR, Nast CC, et al. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest. 2003;112:222–33.PubMed
13.
Nicolau DP, Freeman CD, Nightingale CH, et al. Reduction of bacterial titers by low-dose aspirin in experimental aortic valve endocarditis. Infect Immun. 1993;61:1593–5.PubMed
14.
Nicolau DP, Marangos MN, Nightingale CH, Quintiliani R. Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1995;39:1748–51.PubMedCrossRef
15.
Nicolau DP, Tessier PR, Nightingale CH. Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents. 1999;11:159–61.PubMedCrossRef
16.
Nicolau DP, Tessier PR, Nightingale CH, Quintiliani R. Influence of adjunctive ticlopidine on the treatment of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents. 1998;9:227–9.PubMedCrossRef
17.
Domenico P, Schwartz S, Cunha BA. Reduction of capsular polysaccharide production in Klebsiella pneumoniae by sodium salicylate. Infect Immun. 1989;57:3778–82.PubMed
18.
Polonio RE, Mermel LA, Paquette GE, Sperry JF. Eradication of biofilm-forming Staphylococcus epidermidis (RP62A) by a combination of sodium salicylate and vancomycin. Antimicrob Agents Chemother. 2001;45:3262–6.PubMedCrossRef
19.
Taha TH, Durrant SS, Mazeika PK, Nihoyannopoulos P, Oakley CM. Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis. J Intern Med. 1992;231:543–6.PubMedCrossRef
20.
Chan KL, Dumesnil JG, Cujec B, et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol. 2003;42:775–80.PubMedCrossRef
21.
Chan KL, Tam J, Dumesnil JG, et al. Effect of long-term aspirin use on embolic events in infective endocarditis. Clin Infect Dis. 2008;46:37–41.PubMedCrossRef
22.
Anavekar NS, Tleyjeh IM, Mirzoyev Z, et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin Infect Dis. 2007;44:1180–6.PubMedCrossRef
23.
•• Anavekar NS, Schultz JC, De Sa DD, et al. Modifiers of symptomatic embolic risk in infective endocarditis. Mayo Clin Proc. 2011;86:1068–74. This study showed that embolization risk in patients with endocarditis was significantly less in patients receiving statin therapy, but not with chronic antiplatelet therapy. Neither chronic statin therapy nor aspirin therapy had a significant effect on 6-month mortality.
24.
Serebruany VL, Miller M, Pokov AN, et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol. 2006;97:1332–6.PubMedCrossRef
25.
Tleyjeh IM, Kashour T, Hakim FA, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med. 2009;169:1658–67.PubMedCrossRef
26.
• Snygg-Martin U, Rasmussen RV, Hassager C, Bruun NE, Andersson R, Olaison L. The relationship between cerebrovascular complications and previously established use of antiplatelet therapy in left-sided infective endocarditis. Scand J Infect Dis. 2011;43:899–904. This study showed no significant reduction in cerebrovascular complication rate in endocarditis patients receiving chronic antiplatelet therapy.
27.
• Eisen DP, Corey GR, McBryde ES, et al. Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. J Infect. 2009;58:332–8. This was a randomized trial that showed that recent aspirin therapy was associated with reduced rate of acute valve replacement surgery without a significant effect on rate of embolization or hemorrhagic stroke.
28.
Pepin J, Tremblay V, Bechard D, et al. Chronic antiplatelet therapy and mortality among patients with infective endocarditis. Clin Microbiol Infect. 2009;15:193–9.PubMedCrossRef
29.
•• Habib A, Le KY, Baddour LM, et al. Predictors of Mortality in Patients With Cardiovascular Implantable Electronic Device Infections. Am J Cardiol 2012. This study showed that patients with CIED infection that were on chronic aspirin therapy were less likely to have vegetations on cardiac device leads or heart valves, and less likely to have systemic manifestations of infection. There was no significant difference in mortality or pathogen distribution, however.
30.
Greenspon AJ, Prutkin JM, Sohail MR, et al. Timing of the most recent device procedure influences the clinical outcome of lead-associated endocarditis results of the MEDIC (Multicenter Electrophysiologic Device Infection Cohort). J Am Coll Cardiol. 2012;59:681–7.PubMedCrossRef
31.
Le KY, Sohail MR, Friedman PA, et al. Clinical predictors of cardiovascular implantable electronic device-related infective endocarditis. Pacing Clin Electrophysiol. 2011;34:450–9.PubMedCrossRef
32.
Habib A, Irfan M, Baddour LM, et al. Impact of prior aspirin therapy on clinical manifestations of cardiovascular implantable electronic device infections. Europace 2012.
33.
34.
Hart RG, Kagan-Hallet K, Joerns SE. Mechanisms of intracranial hemorrhage in infective endocarditis. Stroke. 1987;18:1048–56.PubMedCrossRef
Metadaten
Titel
Impact of Antiplatelet Therapy on Clinical Manifestations and Outcomes of Cardiovascular Infections
verfasst von
Ammar Habib
Larry M. Baddour
M. Rizwan Sohail
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Current Infectious Disease Reports / Ausgabe 4/2013
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-013-0347-z

Weitere Artikel der Ausgabe 4/2013

Current Infectious Disease Reports 4/2013 Zur Ausgabe

Hot Topic

Why We Need Crowdsourced Data in Infectious Disease Surveillance

Cardiovascular Infections (D Levine, Section Editor)

Management of MRSA/GISA, VISA Endocarditis

Invited Commentary

Current Challenges in Travelers’ Malaria

Invited Commentary

Expatriates: Special Considerations in Pretravel Preparation

Cardiovascular Infections (D Levine, Section Editor)

Endocarditis Caused by Resistant Enterococcus: An Overview

CARDIOVASCULAR INFECTIONS (D LEVINE, SECTION EDITOR)

Pathophysiology of Infective Endocarditis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise